Trial Profile

Long term phase II clinical trial of DTX-021

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Botulinum-Toxin-A (Primary)
Indications Glabellar lines
Focus Adverse reactions

Most Recent Events

29 Mar 2022 New trial record
24 Mar 2022 According to a Aquavit Pharmaceuticals media release, the company has submitted its IND package (Investigation of New Drug) for a new botulinum toxin (DTX-021) to the FDA for approval and trial will initiate shortly after the approval of the IND.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com